# Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG

> **NCT00037713** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 515 (actual)

## Conditions studied

- Carcinoma, Small Cell Lung

## Interventions

- **BIOLOGICAL:** BEC2 Vaccine

## Key facts

- **NCT ID:** NCT00037713
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** 2002-10
- **Final completion:** 2002-10
- **Target enrollment:** 515 (ACTUAL)
- **Last updated:** 2010-04-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00037713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00037713, "Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00037713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*